2135696-72-7 Usage
General Description
The chemical "(E)-N-(4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide" is a compound consisting of a pyrido[3,4-d]pyrimidin-6-yl group attached to a (3-bromo-4-chlorophenyl)amino group, with a 4-(dimethylamino)but-2-enamide side chain. The compound is characterized by its structure of a pyrido[3,4-d]pyrimidine ring with an attached amide group and a substituted phenyl group. It may have potential pharmaceutical applications due to its structural features and the presence of both an amide and amino groups, which can contribute to its interaction with biological systems in a variety of ways. However, further research and testing are likely necessary to fully understand the properties and potential uses of this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 2135696-72-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,1,3,5,6,9 and 6 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 2135696-72:
(9*2)+(8*1)+(7*3)+(6*5)+(5*6)+(4*9)+(3*6)+(2*7)+(1*2)=177
177 % 10 = 7
So 2135696-72-7 is a valid CAS Registry Number.
2135696-72-7Relevant articles and documents
USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS
-
Paragraph 0049; 0061-0063, (2021/08/06)
Provided herein are methods of selecting cancer patients for treatment with quinazoline-based tyrosine kinase inhibitors, either alone or in combination with anti- HER2/HER3 antibodies, as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with quinazoline-based tyrosine kinase inhibitors alone or in combination with anti -HER2/HER3 antibodies.
